The EAACI Congress includes two presentations with clinical data on bilastine, a compound in development by FAES Farma, S.A. for the treatment of allergic rhinitis, which is partnered with Inspire in the United States and Canada, and one presentation with scientific data on epinastine, bilastine and other antihistamines for treating allergies. -0-
-- A Phase 3 Study Comparing the Efficacy and Safety of Once Daily Bilastine with Cetirizine and Placebo for the Treatment of Seasonal Allergic Rhinitis Poster and brief oral presentation on Tuesday, June 12, 2007 -- Treatment with Bilastine Improves Symptoms in Patients with Seasonal Allergic Rhinitis (Phase 3 Study Comparing the Efficacy and Safety of Once Daily Bilastine with Desloratadine and Placebo for the Treatment of Seasonal Allergic Rhinitis) Poster and brief oral presentation on Tuesday, June 12, 2007 -- Evaluation of Muscarinic Receptor Antagonism by Antihistamines Poster and brief oral presentation on Tuesday, June 12, 2007
The ECFS Conference includes two presentations with clinical data on denufosol, a compound in development by Inspire for the treatment of cystic fibrosis. -0-
-- Deposition and Pharmacokinetic Studies with Inhaled P2Y2 Agonists - Evidence of High Lung Delivery and Minimal Systemic Exposure Poster presentation on Thursday and Friday, June 14-15, 2007 and oral presentation on Thursday, June 14, 2007 -- Reactive Airway Disease and Cystic Fibrosis: a Retrospective Analysis of the Safety and Tolerability with Denufosol Inhalation Solution Poster presentation on Thursday, June 14, 2007 and guided poster tour on Friday, June 15, 2007
The posters from these presentations will be available following each related conference on Inspire's website, www.inspirepharm.com, in the Research & Development section, under Science & Technology.
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, s uccess of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.
Inspire Pharmaceuticals, Inc.
VP, Investor Relations and Corporate Communications
919-941-9777, Extension 219
Dan Budwick, 212-477-9007, Extension 14